Each of five groups of specific-pathogen-free and conventionally reared cats was infected with a different strain of feline calicivirus. Two of the strains were pathogenic, producing characteristically fever, depression, loss of appetite, buccal ulceration, and occasionally increased ocular and nasal secretion. Two of the other strains were mildly pathogenic and associated with fever or buccal ulceration or both; the fifth strain was nonpathogenic. The two pathogenic strains plus three others shown also to be pathogenic were used 3 months after the initial infection to challenge the cats in rearranged groupings. Of the 28 conventional cats challenged, six (21.4%) showed at least a febrile response, although none of the 30 specific-pathogen-free cats showed any clinical signs. After challenge, virus was recovered from throat swabs of 37 of the 58 cats (63.8%) including the six which showed symptoms, but the duration of the excretion of virus was significantly less than that seen with the initial infection. The homologous and heterotypic antibody responses correlated well with the clinical protection, or lack of it, seen on challenge. The results provide further evidence for significant cross-relationships between feline caliciviruses.
Feline caliciviruses (FCV) (feline picornaviruses) have been frequently isolated in many parts of the world; isolations have been made particularly from the respiratory tract of cats with or without clinical signs of inflammation of that tract. Preliminary serological attempts to classify the viruses suggested that numerous distinct serotypes existed (2, 3, 5) .
Subsequent cross-neutralization studies (14) of such isolates led to the suggestion that there were in fact considerable antigenic relationships in the group and that the isolates tested might be regarded as members of a single serotype. It was further postulated (14) that this relationship may reflect in cross-protection in catsinfected with FCV.
To test this postulate, five groups of specificpathogen-free (SPF) and conventionally reared cats were each infected under carefully controlled isolation conditions with an FCV. The clinical and immunological responses of these cats were monitored, and then at 3 months the animals were challenged with either the homologous infecting virus or a heterologous strain, and again their responses were determined.
MATERIALS AND METHODS Viruses. The following FCV isolates were used at the passage level given in parenthesis: M-8 (5th) and N-3 (6th) were Neutralization test. The micro-neutralization test previously described (14) was used. Briefly, sera or nasal secretion samples were diluted in phosphate-buffered saline using 0.05-ml microdiluters in 96-well disposable plates (Microtest II, Falcon Plastics, Oxnard, Calif.). Virus prediluted to a titer of 103-3 TCID,0/ml was then added to 0.05 ml per well and the mixtures was agitated on a Micromixer (Cooke Engineering). After incubation at 37 C in 5% CO2 for 1 h, approximately 104 NLFK cells was added to each well and the plates were reincubated in a CO2-enriched atmosphere for 3 to 4 days until controls showed complete cytopathic effect. Results were recorded as presence or absence of visible cytopathic effect in each well, and 50% end points were calculated by the method of Reed and Muench (16) .
RESULTS
Clinical and virological results of infection are shown in Table 1 .
Cats infected with FCV-M-8. The conventional cats used were found to have pre-inoculation antibody titers to FCV-M-8 of between 1:4 and 1:256. There was no clinical response to infection, but virus was recovered from five of the six cats. The six SPF cats in this group also had neutralizing activity against M-8 present in their sera prior to infection, but levels were minimal (<1:4). The group showed no symptoms after infection, but again virus was recovered from all six cats infected.
Cats infected with FCV-N-3. Only one of the conventional cats showed pre-inoculation homologous antibody, but all six showed titers of 1:2 to 1:200 to the heterologous calciviruses (M-8, 255, etc.). Four of the six conventional cats including the only one with a pre-inoculation neutralizing antibody titer (1:32) showed a febrile response (> 103 F), which in three cases was biphasic, the initial rise being at 2 days and the second between days 4 and 9 post-inoculation. Svmptoms in these four cats varied from occasional sneezing, through clear ocular and/or nasal discharge with tongue ulceration, to frank conjunctivitis, photophobia with purulent ocular and nasal discharge, marked lingual ulceration, transient diarrhea, and general depression. The two remaining conventional cats showed neither febrile response nor symptoms. Virus was recovered from all six cats in the conventional group and three cats were still positive at 37 days but not 57 days postinfection. Of the SPF group, none of which had pre-inoculation antibody, homologous or heterologous, two cats showed a transient fever. Tongue ulcers developed in four cats, and two of these had erosions on the hard palate also. One cat had a vesicle on the lip and another had erosion of the external Cats infected with FCV-F-17. All six conventional cats showed preinoculation homologous neutralizing antibody in their sera (1:2 to 1:10) and some heterologous activity also. In this group no definite febrile response was detected and no cats showed any symptoms, although virus was recovered from all cats. For the SPF group, two of which had minimal levels of homologous neutralizing activity pre-inoculation (<1:8), two cats showed a transient fever, two had lingual ulcers, one had hard-palate erosions and ulceration of the external nares, and one a hard-palate erosion only. Virus was recovered as late as 14 days post-inoculation from four of the six cats in the group.
Cats infected with FCV-255. Two of the conventional cats showed pre-inoculation serum neutralizing activity (1:10 and 1:20). Febrile responses occurred in only two cats and were not clearly biphasic. Only one cat showed any other signs of infection, a solitary tongue ulcer present from days 9 through 11. Virus was recovered from all cats except one between days 4 and 22 post-inoculation. By contrast, the SPF cats, none of which had pre-inoculation serum neutralizing activity, all showed some symptoms including fever (three cats); lingual ulcers particularly of the anterodorsal area (four); hard-palate ulceration (four); mild ocular and nasal discharge (two); conjunctivitis (one); and diarrhea (one). Virus was recovered for up to 5 weeks for all cats.
Cats infected with FCV-FRV. The sera of all six conventional cats had pre-inoculation neutralizing antibody against FCV-FRV of 1:2 to 1:4. No definite febrile response occurred among this conventional group, although one cat showed a lingual ulcer and one showed slight nasal discharge, tongue ulceration, and erosion of the external nares. This latter cat failed to recover from ketamine sedation at 8 weeks post-inoculation. Virus was recovered from all cats between days 2 and 16 post-inoculation. Ulceration of the external nares was a feature of infection in five of the SPF cats including the three which showed preinfection serum neutralizing activity between 1:2 and 1:3. One of the five cats had a nasal discharge and was sneezing. Two cats showed a febrile episode, and virus recovery was successful from five cats.
Cats infected with FCV-FC. A marked conjunctivitis occurred in one of the pair of conventional cats. With the SPF cats, one showed a lingual ulcer and both had ulceration of the external nares.
Cats infected with FCV-CFI. Both conventional kittens showed transient pyrexia, depression, and poor appetite, with conjunctivitis and erosions on the hard palate in one. Appetite was similarly depressed in the SPF cats, and one had a solitary lingual ulcer.
Cats infected with FCV-5936. Transient pyrexia occurred in both conventional kittens, with conjunctivitis, nasal discharge, and sneezing in one. On autopsy, at 7 days postinfection, foci of interstitial pneumonia were present in the second kitten. The two SPF kittens showed fever, anorexia, and tongue and external nares ulcers, with nasal discharge in one kitten.
Serological response to primary infection. (i) Serum. Tables 2 through 6 show the development of neutralizing antibody in each group, both against the original infecting virus and against some of the other FCV under study, that is, the homologous and heterologous response. The homologous response is shown graphically in Fig. 1 and the means between groups for the heterologous responses are sho,.-n in Fig. 2. (ii) Nasal secretion. Many samples proved cytotoxic at low dilutions, and nasal secretion neutralizing activity was in general of low order (< 1:16). Many of the conventional cats showed low-level homologous and heterologous virus neutralization in pre-exposure samples, but apart from two SPF cats in the M-8-infected group (titers of 1:4 and 1:7), none of the SPF cats showed such preinfection activity. After infection, the majority of the conventional cats showed neutralizing ability of nasal secretions but, apart from cats in the M-8-infected group, where titers reached as high as 1:200 at 4 weeks post-inoculation, titers were between 1:2 and 1:16. For the SPF animals, the peak titers reached were 1:20, but many animals failed to show detectable activity.
Clinical response to challenge at 12 weeks post-inoculation. This is summarized in table 7 . There was no clinical response to the challenge infections in any cat originally infected with either M-8 or N-3 viruses. Of the cats infected initially with F-17 virus, two of the conventional group, both receiving FC as the challenge virus, showed, respectively, transient fever with a solitary lingual vesicle and a lingual ulcer without fever. Three cats, all in the conventional group, which had been infected with 255 virus gave a clinical response to challenge. Of these, one cat, challenged with virus 5936, showed fever and erosion of the external nares, and the other two cats, both challenged, as they had been initially infected, with 255 virus, showed fever, anorexia, nasal discharge, other studies (15) (4, 10, 12, 13) . The ciated with at least experimental FCV in-neutralizing activity present in nasal secretions on has been noted previously (8, 15) Viral shedding by the majority of cats postchallenge, in the absence of any clinical symptoms and in the presence of antibody, is not unexpected, having been noted previously with FCV challenge (15) and with other viruses, for instance human rhinovirus (4) . It is quite apparent, however, that the duration of excretion after challenge (overall mean, 3.1 days) was much shorter than after initial infection (overall mean, 11.3 days). Bartholomew and Gillespie (1) reported that cats recovered from infection with FCV-CFI did not resist challenge with FCV-FJ, but their criteria for this were clinical illness and/or virus isolations, so it is not clear whether any of the cats challenged showed clinical signs.
Of the six cats that showed any symptoms after challenge, only two were significantly severe. These were cats which were challenged, as well as primarily infected, with FCV 255. With these cats, although neither had preinoculation antibody to FCV 255, the clinical response to the original infection had been mild and one cat did not yield virus after infection. The low serological response correlated with this, but after challenge titers rose to a level on a par with the rest of the group.
Based on the results of the challenge experiment, it would seem that serum neutralizing titer of 4.0 (1:16) or greater indicates protection against challenge with various FCV, at least at the 106 3 TCID5o challenge level. Further, a serum neutralizing titer of 2.6 (1:7) or less correlates with susceptibility to challenge with heterologous FCV. The protective titer of neutralizing activity in nasal secretion is difficult to quantify, but all 20 cats that had such activity detectable (mean level, 2.3 or 1:5) did resist challenge clinically although they still showed transient virus shedding (mean duration, 2.6 days).
The likely persistence of the antibody response is impossible to forecast, but there is no tendency for decline of titers up to 8 weeks post-challenge.
It would have been desirable to include in the experiment some FCV isolates from other parts of the world besides the United States, but importation licenses were impossible to obtain at the time. The extensive cross-neutralizing activity previously reported (14) , however, which included results using isolates from several countries, would indicate that a valid extrapolation could be made of the in vivo cross-protection obtained with the isolates currently tested, to incorporate most, if not all, feline caliciviruses. Work will continue to test this hypothesis.
